Please login to the form below

Not currently logged in
Email:
Password:

J&J and Elan close deal

J&J and Elan agree deal for Alzheimer's Immunotherapy Programme and investment plan

Johnson & Johnson's (J&J) newly formed subsidiary Janssen Alzheimer Immunotherapy has acquired all the assets and rights of Elan related to its Alzheimer's Immunotherapy Programme (AIP).

As part of the deal, through its affiliate Janssen Pharmaceutical, J&J has invested $885m in exchange for newly issued American Depositary Receipts (ADRs) of Elan, which represents 18.4 per cent the firm's outstanding ordinary shares.

The AIP represents Elan's interest in a collboration with Wyeth Pharmaceuticals to research, develop and commercialise selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease.

Janssen Alzheimer Immunotherapy will take over Elan's activities with Wyeth under the terms of the AIP and will develop activities for bapineuzumab, a potential first-in-class treatment being evaluated for slowing the progress of Alzheimer's.

The AIP includes multiple compounds being evaluated for slowing the progression of the disease. Lead compound, bapineuzumab, administered intravenously once every three months, is currently in phase III trials. In addition, a subcutaneous formulation administered once a week is in phase II trials, as is a vaccine for Alzheimer's.

17th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics